Evidence map›Paper›PMID 37933610›Full record

ReviewActa ophthalmologica2023

Multimodal imaging and deep learning in geographic atrophy secondary to age-related macular degeneration.

Maximilian Pfau, Sandrine H Künzel, Kristina Pfau, Steffen Schmitz-Valckenberg, Monika Fleckenstein, Frank G Holz

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Acta ophthalmologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06536062 (Age-related Macular Degeneration of Atrophic Type Treated With Intravitreal Injection of Umbilical Cord Blood Enriched With Platelet Plasma), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06536062 narecruitingnot on this mapstarted 2024, after this paper: background citation

Age-related Macular Degeneration of Atrophic Type Treated With Intravitreal Injection of Umbilical Cord Blood Enriched With Platelet Plasma: Multicenter Study.

TypeinterventionalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2024 to 2026Enrolled36ConditionsDry Age-related Macular DegenerationArmsIntravitreal injection of CB-PRP
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Maximilian PfauInstitute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-9761-9640
Sandrine H KünzelDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Kristina PfauInstitute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
Steffen Schmitz-ValckenbergDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Monika FleckensteinDepartment of Ophthalmology & Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.
Frank G HolzDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
University of Bonn · DEUniversity of Basel · CHUniversity of Utah · US

Funding

University of Utah, Core Vision Research GrantP30EY014800 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Bryan William Jones · 2005 to 2026
$14.6M
The Impact of Non-Exudative Type 1 Macular Neovascularization (MNV) on Age-related Macular Degeneration (AMD) ProgressionR01EY033365 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Monika Fleckenstein · 2022 to 2026
$1.9M
Progression of Early Atrophic Lesions in Age-related Macular degenerationR01EY034965 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Monika Fleckenstein, Steffen Schmitz-Valckenberg · 2023 to 2026
$1.5M
NEI NIH HHS EY014800NEI NIH HHS P30 EY014800NEI NIH HHS R01 EY033365NEI NIH HHS R01EY033365NEI NIH HHS R01 EY034965NEI NIH HHS R01EY034965
6 · The paper itself

Abstract

Geographic atrophy (GA) secondary to age-related macular degeneration is among the most common causes of irreversible vision loss in industrialized countries. Recently, two therapies have been approved by the US FDA. However, given the nature of their treatment effect, which primarily involves a relative decrease in disease progression, discerning the individual treatment response at the individual level may not be readily apparent. Thus, clinical decision-making may have to rely on the quantification of the slope of GA progression before and during treatment. A panel of imaging modalities and artificial intelligence (AI)-based algorithms are available for such quantifications. This article aims to provide a comprehensive overview of the fundamentals of GA imaging, the procedures for diagnosis and classification using these images, and the cutting-edge role of AI algorithms in automatically deriving diagnostic and prognostic insights from imaging data.

Indexed as

Deep LearningGeographic AtrophyMacular DegenerationArtificial IntelligenceFluorescein AngiographyHumansMultimodal ImagingTomography, Optical Coherenceage-related macular degenerationartificial intelligencegeographic atrophyimaging biomarkersmultimodal imaging

Identifiers

PMID37933610
PMCPMC11044135
OpenAlexW4388449163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.